Article Data

  • Views 603
  • Dowloads 132

Case Reports

Open Access

Tertiary cytoreduction for recurrent endometrial cancer

  • F. Bellati1,2
  • A. Papadia1
  • M.L. Gasparri1,2,*,
  • P. Scanagatta3
  • F. Carriero3
  • P. Benedetti Panici2
  • F. Raspagliesi1

1Division of Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

2Department of Gynecology and Obstetrics, “Sapienza” University of Rome, Rome, Italy

3Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

DOI: 10.12892/ejgo3558.2017 Vol.38,Issue 1,February 2017 pp.132-134

Published: 10 February 2017

*Corresponding Author(s): M.L. Gasparri E-mail: marialuisa.gasparri@uniroma1.it

Abstract

This paper reviews the surgical approach experiences in endometrial cancer recurrence and presents for the first time data on the surgical management of endometrial cancer patients at the time of their second recurrence. Surgery could represent a pivotal role in selected cases of recurrent endometrial cancer, offering long-term complete remissions and a survival advantage.

Keywords

Recurrent endometrial cancer; Salvage surgery; Metastasectomy.

Cite and Share

F. Bellati,A. Papadia,M.L. Gasparri,P. Scanagatta,F. Carriero,P. Benedetti Panici,F. Raspagliesi. Tertiary cytoreduction for recurrent endometrial cancer. European Journal of Gynaecological Oncology. 2017. 38(1);132-134.

References

[1] Papadia A., Bellati F., Ditto A., Bogani G., Gasparri M.L., Di Donato V., Martinelli F., et al.: “Surgical treatment of recurrent endometrial cancer: time for a paradigm shift”. Ann. Surg. Oncol., 2015, 22, 4204.

[2] Scarabelli C., Campagnutta E., Giorda G., DePiero G., Sopracordevole F., Quaranta M., DeMarco L.: “Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma”. Gynecol. Oncol., 1998, 70, 90.

[3] Campagnutta E., Giorda G., De Piero G., Sopracordevole F., Visentin M.C., Martella L., Scarabelli C.: “Surgical treatment of recurrent endometrial carcinoma”. Cancer, 2004, 100, 89.

[4] Awtrey C.S., Cadungog M.G., Leitao M.M., Alektiar K.M., Aghajanian C., Hummer A.J., et al.: “Surgical resection of recurrent endometrial carcinoma”. Gynecol. Oncol., 2006, 102, 480.

[5] Bristow R.E., Santillan A., Zahurak M.L., Gardner G.J., Giuntoli R.L. 2nd, Armstrong D.K.: “Salvage cytoreductive surgery for recurrent endometrial cancer”. Gynecol. Oncol., 2006, 103, 281.

[6] Ren Y., Shan B., Shi D., Wang H.: “Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study”. BMC Cancer, 2014, 14, 135.

[7] Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S.: “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study”. J. Clin. Oncol., 2004, 22, 3902.

[8] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2004, 22, 2159.

[9] Thigpen T., Brady M.F., Homesley H.D., Soper J.T., Bell J.: “Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2001, 19, 364.

[10] Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T.: “Highdose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 1996, 14, 357.

[11] Whitney C.W., Brunetto V.L., Zaino R.J., Lentz S.S., Sorosky J., Armstrong D.K., et al.: “Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 4.

[12] Westin S.N., Rallapalli V., Fellman B., Urbauer D.L., Pal N., Frumovitz M.M., et al.: “Overall survival after pelvic exenteration for gynecologic malignancy”. Gynecol. Oncol., 2014, 134, 546.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top